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1607-551X/Copyright ª 2015, KaohsiuAbstract Radiofrequency ablation (RFA) is an effective and real-time targeting modality for
small hepatocellular carcinomas (HCCs). However, mistargeting may occur when the target
tumor is confused with cirrhotic nodules or because of the poor conspicuity of the index
tumor under ultrasonography (US). Real-time virtual sonography (RVS) can provide the
same reconstruction computed tomography images as US images. The aim of this study is
to investigate the usefulness of RVS-assisted RFA for HCCs that are inconspicuous or conspicu-
ous under US. A total of 21 patients with 28 HCC tumorsddivided into US inconspicuous and
high-risk subgroup (3 tumors in 3 patients), US inconspicuous and nonhigh-risk subgroup (5 tu-
mors in 4 patients), US conspicuous and high-risk subgroup (16 tumors in 14 patients), and US
conspicuous and nonhigh-risk subgroup (4 tumors in 3 patients)dunderwent RVS-assisted RFA
between May 2012 and June 2014 in our institution. The mean diameter of the nodules was
2.0  1.1 cm. The results showed that the complete ablation rate is 87.5% (7/8) in the US
undetectable group and 75% (15/20) in the US detectable group. A comparison between six
tumors with incomplete ablation and 22 tumors with complete ablation showed higher
alpha-fetoprotein level (mean, 1912 ng/mL vs. 112 ng/mL) and larger tumor size (mean diam-
eter, 26 mm vs. 16 mm) in the incomplete ablation nodules (both p < 0.05). In conclusion, RVS-
assisted RFA is useful for tumors that are difficult to detect under conventional US and mayeclare no conflicts of interest.
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mistargeting.
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Hepatocellular carcinomas (HCCs) are one of the most
common malignancies and major causes of mortality
worldwide [1e3]. Treatment for HCCs depends on the
tumor stage and liver function. Locoregional treatments,
including percutaneous ethanol injection (PEI) and radio-
frequency ablation (RFA), have been considered effective
modalities for small HCCs [4e6]. Of these, percutaneous
ultrasonography (US)-guided RFA is an effective, fast, and
real-time targeting modality for small HCCs [5e7]. How-
ever, mistargeting may occur for several reasons: when the
target tumor is confused with cirrhotic nodules; poor
conspicuity of the index tumor under US [8e10]; safety
concerns during repeat RF electrode placement for tumors
in high-risk locations, which are close to the hepatic
capsule, vital organs, vessels, or central bile ducts [7e9].
Real-time virtual sonography (RVS) can provide the same
multiplanar reconstruction computed tomography (CT) or
magnetic resonance images as US images under real-time
US monitor screen. Some studies have shown the useful-
ness of RVS-assisted local treatment of HCCs that are poorly
detected by conventional US, but so far no study has been
conducted in terms of RVS-assisted RFA for HCCs in high-risk
locations [7,11,12]. The aim of this study is to investigate
the efficacy of RVS-assisted RFA for HCCs that are incon-
spicuous on conventional US or are situated in high-risk
locations.Materials and methods
Patients
In this retrospective study, we reviewed the prospective
records of consecutive patients with HCC treated with
RVS-guided RFA in our department between May 2012
and June 2014. All index HCCs were diagnosed by
cytology, pathology, or according to the criteria of the
American Association for the Study of Liver Disease [6]. All
patients had cirrhosis with ChildePugh class A or B. None of
them have extrahepatic metastasis or intrahepatic vessel
invasion. Impaired coagulopathy was required to be cor-
rected prior to the treatment (prothrombin time < 3 sec-
onds, platelet concentration > 50,000 cells/mm3). All
patients received RFA after a comprehensive discussion
during our HCC multidisciplinary meeting. Informed con-
sent was obtained from each patient prior to the treat-
ment. This study was approved by the Institutional Review
Board, Linkuo Chang Gung Memorial Hospital, Taoyuan,
Taiwan.Study design
A total of 23 patients diagnosed with HCC were treated with
RVS-guided RFA in our department between May 2012 and
June 2014. All patients have HCC nodules that are either
inconspicuous under conventional US or in high-risk loca-
tions but can be clearly depicted under dynamic CT. A
detectable lesion under conventional US was defined as a
lesion where the margin and echogenicity of the index
tumor are visible, whereas an undetectable lesion is one in
which the margin and echogenicity of index tumor are not
visible. The high-risk locations were defined as < 5 mm
from the liver capsule, a large vessel, or an extrahepatic
vital organ. Patients with more than three nodules were
excluded from this study and might receive other types
of treatment, such as transarterial chemoembolization
(TACE). Patients with a follow-up of at least 3 months after
treatment were enrolled in this study. To evaluate the
effects of RVS-guided RFA and to minimize bias, we
enrolled only patients who were not undergoing other types
of treatment, such as PEI, RFA, or even TACE, within the
past 2 months. Two patients were excluded for receiving
RFA within 30 days prior to RVS-guided RFA. A total of 28
HCC nodules were retrospectively analyzed in 21 patients
(18 males and 3 females, mean age 69.5 years) treated with
RVS-guided RFA (Table 1).
CT and magnetic resonance imaging protocol
CT or magnetic resonance imaging (MRI) examinations were
performed within 1 month prior to RFA using a four-phase
method. These four dynamic phases were precontrast,
arterial, portal, and delayed. The slice thickness of CT was
5 mm, and the table feed was 5 mm/s. One hundred mil-
liliters of nonionic contrast material [iopamidol (Iopamiron
370); Bayer Yakuhin, Osaka, Japan] at a rate of 3.5 mL/s
using a power injector (Nemoto Kyorindo, Tokyo, Japan)
was injected into each patient. In the dynamic MR images,
arterial and portal phases were obtained after injection
of gadoliniumediethylenetriamine pentaacetic acid (gado-
pentetate dimeglumine) or gadoliniumeethoxybenzyle
diethylenetriamine pentaacetic acid (Gd-EOB-DTPA;
gadoxetate disodium) [13,14]. The size of the HCC nodule
was determined by either the arterial or portal phase,
depending on which phase could best depict the nodule.
To assess the treatment effect of RFA, dynamic CT or MRI
using 5-mm-slice scans was performed within 1 month after
RFA. Those scans were repeated approximately every 3
months if there was no local tumor progression (LTP). LTP
was diagnosed if follow-up dynamic CT or MRI revealed a
new lesion that had developed close to a previous ablation
area [7].
Table 1 Baseline characteristics of 21 patients (28 tu-
mors) undergoing RFA by real-time virtual sonography
assistance for hepatocellular carcinoma.
Variables Mean  SD (range) or n (%)
Age (y) 69.6  8.5 (57.0e85.0)
Sex (male) 18 (85.7)
Virus/alcoholic/Cryptogenic 19:1:1 (90.4:4.8:4.8)
ChildePugh A/B 20:1 (95.2:4.8)
Treatment naı¨ve 4 (19.0)
Ascites 1 (4.8)
PT/INR 1.2  0.1 (1.0e1.7)
Bilirubin T (mg/dL) 1.0  0.4 (0.2e2.0)
Albumin (g/dL) 3.70  0.44 (3.00e4.50)
AFP (ng/mL) 391  1119 (1.9e5535)
Platelet (1000/mm3) 90  29 (36e154)
Tumor size (mm) 20  11 (7e45)
US conspicuous 20 (71.4)
Left/right lobes 7:21 (25:75)
High-risk location 19 (67.9)
Complete ablation 22 (78.6)
Follow-up days 362  234 (121e817)
Data are presented as mean  standard deviation.
AFPZ alpha-fetoprotein; INRZ international normalized ratio;
PT Z prothrombin time; RFA Z radiofrequency ablation;
US Z ultrasonography.
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The RVS system comprised an ultrasound scanner, a position
sensor unit (EZU-RV3S; Hitachi, Tokyo, Japan; a magnetic
sensor unit for RVS), and a computer with RVS software
(EZU-RV8; Hitachi). Multiplanar reconstruction images were
reconstructed using CT or MRI. The previously acquired CT
or MRI data were loaded onto US. The patients were placed
in a supine position, with shoulders, buttocks, and heels in
contact with the table. While the operator handled real-
time US, the ultrasound machine generated multiplanar
reconstruction images from the CT volume or MRI data,
corresponding to the US images of the same or very similar
cross section. The magnetic sensor on the sonography probe
precisely captured the magnetic field alternation of the
position, direction, or rotation via the transmitter placed at
the patient’s left flank. Thus, we could mark the target
lesion detected on CT/MRI and find some fiducial landmarks
(e.g., vessels or organs). Virtual images with marks were
revisualized while using conventional US that helped the
operator perform RFA.
RFA protocol
Prior to RFA, the three-dimensional anatomical relation-
ships between the target nodules and intrahepatic vessels
or vital organs were sufficiently examined, and the dis-
tances were measured on RVS. RFA was performed percu-
taneously under RVS guidance. Straight electrodes with a
3- or 2-cm active tip were used (Figure 1). For enlarging an
ablation area, we often used a multiple overlapping abla-
tion technique during the treatment. Artificial ascites or
pleural effusion techniques were established when thetarget nodule was close to the critical organs or located
near the hepatic dome [7,15,16]. Patients with refractory
ascites, portal vein tumor thrombosis, or extrahepatic
metastasis were excluded in our study. We only used the
automatic mode of RF emission in this study. Radio-
frequency energy was delivered for 9e12 minutes in each
site [7,15,16]. RFA was performed by three experienced
hepatologists (C.C. Lin, W.T. Chen, S.M. Lin) who have > 5
years of experience in handling RFA cases in our hospital
[4,17,18].
Statistical analyses
Statistical analyses were carried out using the SPSS soft-
ware, version 20.0 (SPSS Inc., Chicago, IL, USA). Descriptive
data with a normal distribution are reported as
mean  standard deviation. Stepwise logistic regression
analyses were used to determine the correlation of the
predictive factors to clinical outcomes. Student t test and
ManneWhitney U test were used to assess the differences
between groups in normal-distributed and nonnormal-
distributed groups. A two-tailed p < 0.05 was considered
statistically significant.
Results
Between May 2012 and June 2014, there were 25 patients
with HCCs who have undergone RVS-guided local ablation in
our department. Four patients were excluded from this
study because two patients underwent RVS-guided PEI, one
received TACE therapy, and another patient received RFA
within 2 months prior to RVS-guided RFA. Overall, this left
us with 21 patients, which comprised 18 males and three
females with a total of 28 HCC nodules (Table 2). Fifteen
patients had a single nodule, five patients had two nodules,
and one patient had three nodules. Their mean age was
69.4 (range 57e85) years. All patients were diagnosed with
liver cirrhosis via imaging or biopsy. The etiology of un-
derlying diseases included Hepatitis B or Hepatitis C in 19
(90.4%) patients, alcohol consumption in one (4.8%) pa-
tient, and cryptogenic etiology in one (4.8%) patient.
Twenty patients had ChildePugh A and one patient had
ChildePugh B (score Z 7) cirrhosis. The mean diameter of
the 28 HCC nodules was 1.9  1.1 (range 0.7e4.5) cm.
Among the 28 target lesions, seven nodules were located at
the left lobe and the other 21 nodules were in the right
lobe. Eight (3 in high-risk group, 5 in nonhigh-risk group)
lesions were inconspicuous on conventional US, whereas 20
lesions were conspicuous on conventional US, and of the 28
lesions, 19 (3 inconspicuous and 16 conspicuous) nodules
were found in high-risk locations. In the eight HCC nodules
inconspicuous by US, six of them were very vague under
sonography, and the other two nodules were very close to
the previous TACE or RFA site (Figure 1). All eight index
tumors (in 8 patients) that were inconspicuous on conven-
tional US had been treated with RFA, PEI, or TACE for other
HCC nodules over 2 months prior to RVS-assisted RFA.
However, after previous HCC treatments for other HCC
nodules, the index tumors remained inconspicuous on
conventional US. All the lesions that could not be detected
on conventional US could be visualized on CT. They could
Figure 1. An 80-year-old male patient with a recurrent HCC after a previous RFA in segment 4 near the hepatic dome. RVS-guided
RFA was performed. (A) A hyperdense HCC nodule (arrow) abutting the former ablation lesion at arterial phase on CT. (B) Hypo-
dense lesion at delayed phase on CT. (C) Although the lesion is inconspicuous on conventional sonography, it was easily located
using the RVS system. The target lesion is marked with a circle (left) prior to RFA. When the electrode correctly punctured the
tumor, the corresponding MPR picture revealed the mark that we had previously set up. (D) Ablation is completed. CTZ computed
tomography; HCC Z hepatocellular carcinoma; MPR Z multiplanar reconstruction; RFS Z radiofrequency ablation; RVS Z real-
time virtual sonography.
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362 (range 121e817) days.
Among the 21 patients, four were treatment-naı¨ve,
seven had received RFA only (mean 19.1 months, range
2.3e68 months), and 10 had undergone TACE or TACE plus
RFA (mean 9.8 months, range 2.2e20.7 months) prior to
RVS-assisted RFA. The RF electrodes were inserted to all 28
HCC nodules with RVS assistance. There were no major
complications except in one patient, who had a 4.5-cm
tumor at segment 8 near the attached colon at the dome
area receiving three placements of RVS-assisted RFA; in this
instance, a severe complication developed in the form of
pneumoperitoneum due to a thermal injury that was
detected 1 day after RFA. A right hemicolectomy was per-
formed to address this setback, and the patient recovered
after the operation.
Contrast-enhanced CT was performed within 1 month to
evaluate whether complete ablation had been achieved.
Twenty-two of the 28 (79%) HCC nodules achieved complete
ablation after the first RFA course (Table 3). As for the eight
target lesions that were inconspicuous on conventional
US, seven (87.5%) nodules achieved complete ablation. In
the US conspicuous group, 15 (75%) of the 20 tumors ach-
ieved complete ablation. A comparison between six tumors
with incomplete ablation and 22 tumors with completeablation showed higher alpha-fetoprotein (AFP; mean,
1912 ng/mL vs. 112 ng/mL) and larger tumor size (mean
diameter, 26 mm vs. 16 mm) in the incomplete ablation
nodules (both p < 0.05; Table 4). Because the AFP level
reached 5535 ng/mL in Patient 13 (Table 2), the AFP level in
the US conspicuous group was slightly significantly higher
than that in the US inconspicuous group (Table 4).Discussion
Percutaneous US-guided RFA is an accurate and effective
curative modality for small HCCs [4e7]. Most small HCCs
can be successfully ablated with US-guided RFA; however,
for tumors inconspicuous under US but detectable by CT or
MRI, US-guided RFA under CT or MRI navigation using the
novel RVS device is more feasible and useful.
This issue indicates that in cases where mistargeting may
be encountereddsuch as when the target tumor is
confused with cirrhotic nodulesdRVS-assisted RFA is a
useful option [8e10]. The current results confirm the use-
fulness of RVS-assisted RFA for tumors undetectable on US.
Moreover, concerning the complication after the placement
of RF electrodes for tumors in high-risk locations, our study
also shows a beneficial result of RVS-assisted RFA for HCCs
Table 2 Baseline characteristics of patients and tumors.a
Patient
no.
Tumor
no.
Sex/age Size (cm) Location US
conspicuous
High-
risk
location
Childe
Pugh
score
AFP
(ng/dL)
Complete
ablation
LTP (d)a Follow-up (d)
1 1 M/68 1.7 S3 N N 6 402 Y 315 370
2 2 M/80 1 S8 Y N 5 32 Y 214 472
2 3 M/80 1 S7 N N 5 32 Y N 472
2 4 M/80 1.5 S8 Y N 5 32 Y N 472
3 5 M/66 4.4 S5 N N 5 197 Y N 452
4 6 M/61 1.6 S7 Y N 5 14.5 Y 351 403
4 7 M/61 0.9 S7 N N 5 14.5 Y N 403
5 8 M/66 2 S8 N Y 5 78 Y N 252
6 9 M/60 1.3 S3 Y N 7 4.6 Y N 758
6 10 M/60 0.7 S7 Y Y 7 4.6 Y N 758
7 11 F/64 1 S4 Y Y 6 984 Y N 403
8 12 M/79 3.4 S6 N Y 6 208 Y 90 178
9 13 F/57 1.7 S6 Y Y 5 91 Y N 817
10 14 M/65 1 S7 Y Y 5 1.9 Y 158 784
10 15 M/65 1 S8 N N 5 1.9 Y N 784
11 16 M/75 3.1 S5/6 Y Y 6 4.4 Y N 377
12 17 M/75 2 S4 N Y 6 140 N d 288
13 18 M/63 3.9 S8 Y Y 5 5535 N d 121
13 19 M/63 2.4 S8 Y Y 5 5535 N d 121
14 20 M/84 4.5 S4 Y Y 5 26 N d 163
15 21 M/81 1.3 S8 Y Y 6 79 Y N 139
16 22 M/85 1.6 S8 Y Y 5 2.9 Y N 141
17 23 M/66 2.3 S3/4 Y Y 5 12.2 Y N 749
18 24 M/72 1 S6 Y Y 5 159 Y N 190
18 25 M/72 1.6 S8 Y Y 5 159 N d 190
19 26 M/58 1.4 S8 Y Y 5 74 N d 188
20 27 M/66 1.2 S8 Y Y 5 23 Y N 160
21 28 F/71 1.6 S2 Y Y 6 137 Y N 197
AFP Z alpha-fetoprotein; F Z female; LTP Z local tumor progression; M Z male; US Z ultrasonography.
a No LTP evaluation for tumor numbers 15, 16, 17, 18, 20, and 21 for incomplete ablation.
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ities for tumors in cirrhotic background and high-risk loca-
tions, our studydnotwithstanding the fact that it is based
on a small sample sizedis still able to provide promising
results in terms of effective and safe RFA.
RVS-assisted RFA is a relatively novel device that has
been introduced in recent years to treat lesions that are
unclear under conventional US. Earlier studies were also
based on small sample sizes [8e10,19]; however, these
studies had confirmed that RVS assistance can improve the
conspicuity of HCCs and the feasibility of percutaneous RFA
for HCCs that are not visible on conventional US. In real-
world practice, the majority of index tumors are visible
on US without RVS assistance. Therefore, we aimed to
elucidate the usefulness of RVS-guided RFA for tumors that
are inconspicuous on conventional US and/or situated in
high-risk locations. Although the sample size is small
because this novel device has only been made available
recently, our results still showed that RVS-assisted RFA is
useful for tumors difficult to detect on conventional US and
may be useful for tumors in high-risk locations because it
may prevent complications induced by mistargeting.
In the study by Nakai et al. [20], all 20 enrolled patients
with HCCs who underwent RVS-assisted RFA achievedcomplete ablation, and no local tumor progression was
observed during the study period (9e18 months) [10].
However, these patients had single HCC only. In our study,
21 patients with 28 tumors were considered difficult for RFA
because majority of these tumors were either in high-risk
locations, inconspicuous under conventional US, or both.
Of the eight tumors in the US inconspicuous group, the rate
of complete ablation after one session of RFA was 87.5%
(7 of 8), which was comparable to that of tumors in
nonhigh-risk locations after RFA without RVS assistance by
indirect comparison with similar study groups [17,18,20].
The patient with incomplete ablation underwent a second
RFA and achieved complete ablation. No local tumor
recurrence was noted after 10 months of follow-up. In the
22 tumors with complete ablation, 13 (59.1%) tumors were
in high-risk locations. Moreover, as for the six tumors with
incomplete ablation, all of them (100%) were in high-risk
locations.
As for ablation-naı¨ve tumors or viable tumors after
previous treatment, which are probably undetectable
under conventional US, these lesions could always be
detected via dynamic CT or MRI, and are thereafter visible
in RVS. The operator should evaluate the three-dimensional
anatomical relationships between the target tumors and
Table 3 Baseline characteristics of tumors in groups with complete ablation and incomplete ablation.
Variables Complete ablation (N Z 22) Incomplete ablation (N Z 6) p
Age (y) 69.0  8.6 (61e80) 69.2  9.6 (58e84) 0.849
Sex (male) 19 (86.4) 6 (100.0) > 0.99
Virus/Alcoholic/Cryptogenic 19:2:1 (86.4:9.1:4.5) 6/0/0 (100.0:0:0) 0.632
ChildePugh A/B 20/2 (90.9/9.1) 6/0 (100/0) > 0.99
Ascites 1 (4.5) 0 (0) > 0.99
Treatment naı¨ve 5 (21.7) 0 (0) 0.550
PT/INR 1.1  0.1 (1.0e1.3) 1.2  0.1 (1.1e1.3) 0.682
Bilirubin (total, mg/dL) 1.05  0.30 (0.6e1.5) 0.88  0.56 (0.5e2.0) 0.236
Albumin (g/dL) 4.03  0.53 (3.00e4.50) 3.85  0.34 (3.40e4.30) 0.427
AFP (ng/mL) 112  162 (2e402) 1912  2807 (26e5535) 0.045
Platelet (1000/mm3) 105  47 (36e154) 96  28 (64e126) 0.935
Tumor size (mm) 16  9 (9e34) 26  13 (14e45) 0.033
High-risk location 13 (59.1) 6 (100.0) 0.136
Follow-up days 435  198 (178e784) 179  62 (121e288) 0.005
Data are presented as mean  SD (range) or n (%).
AFPZ alpha-fetoprotein; INRZ international normalized ratio; LTPZ local tumor progression; PTZ prothrombin time; SDZ standard
deviation.
418 C.-H. Lee et al.intrahepatic or extrahepatic vasculature, diaphragm, or
other landmarks prior to the RFA procedure. The target
point of the RFA electrode tip can be marked on the US
monitor screen simultaneously; this makes ablation easier
to perform because the marks are displayed and the probe
can be precisely aimed at the target lesion. After the pre-
cise targeting of tumors, RVS-assisted RFA not only achieves
a more effective ablation, but can also prevent potential
complications after ablation. In this study, only one
severe complication was encounteredda patient devel-
oped pneumoperitoneum due to colon thermal injury, but
this individual recovered after the operation.
Based on our study, a satisfactory outcome is achieved
with RVS-assisted RFA for tumors undetectable on US. We
may therefore expand the utilization of RVS-assisted RFA toTable 4 Baseline characteristics of tumors in ultrasonography i
Variables US inconspicuous (N Z 8
Age (y) 70.8  7.9 (61e79)
Sex (male) 8 (100.0)
Virus/Alcoholic/Cryptogenic 8:0:0 (100:0:0)
ChildePugh A/B 8:0 (100.0:0)
Ascites 1 (12.5)
Treatment naı¨ve 0 (0.0)
PT/INR 1.2  0.1 (1.0e1.3)
Bilirubin (total, mg/dL) 1.1  0.3 (0.8e1.5)
Albumin (g/dL) 3.80  0.56 (3.30e4.50)
AFP (ng/mL) 191  162 (15e402)
Platelet (1000/mm3) 81  43 (36e137)
Tumor size (mm) 20  10 (9e34)
High-risk location 3 (37.5)
Complete ablation 7 (87.5)
Follow-up days 310  100 (178e403)
Data are presented as mean  SD (range).
AFPZ alpha-fetoprotein; INRZ international normalized ratio; LTPZ
deviation; US Z ultrasound.HCCs under these situations; although CT-guided RFA can
be an alternative to US-guided RFA, the former seems
cumbersome and requires a longer procedure time [21].
Although RVS-guided RFA could not greatly improve the
technical effectiveness for tumors in high-risk locations,
the major complication that ensued was trivial. However, it
should be noted that the sample size used in this study was
small, and the results were derived from a retrospective
analysis. Further study with a larger sample size may be
required.
In conclusion, our preliminary results based on a small
sample size demonstrate that RVS-assisted RFA is useful for
tumors that are difficult to detect on conventional US and
may be useful for tumors in high-risk locations because it
may prevent complications induced by mistargeting.nconspicuous and conspicuous groups.
) US conspicuous (N Z 20) p
68.3  9.4 (58e84) 0.636
17 (85.0) 0.536
17:2:1 (85.0:10.0:5.0) 0.511
18:2 (90.0:10.0) > 0.99
0 (0) 0.286
5 (25.0) 0.281
1.1  0.1 (1.0e1.2) 0.980
0.9  0.5 (0.5e2.0) 0.862
4.01  0.38 (3.50e4.50) 0.304
1422  2539 (2e5535) 0.469
110  33 (64e154) 0.862
22  13 (10e45) 0.672
16 (80.0) 0.030
15 (75.0) 0.640
305  234 (121e784) 0.500
local tumor progression; PTZ prothrombin time; SDZ standard
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